

The Incidence Of Occult Hepatitis B Among
HCV Chronic Patients (Responders and Non-
responders) Receiving Combined Therapy

Thesis

*Submitted for Partial fulfillment of
M.Sc. Degree in Internal Medicine*

By

Ahmed Mostafa Ahmed Ibrahim
M.B.B.Ch

Supervised by:

Prof. Dr. Yehia Mohamed El-Shazly
Professor of Internal Medicine
Faculty of Medicine
Ain Shams University

Assist. Prof. Dr. Khaled Zakaria El-Karmoty
Assistant Professor of Internal Medicine
Faculty of Medicine
Ain Shams University

Dr. Ahmed Ali Monis
Lecturer of Internal Medicine
Faculty of Medicine
Ain Shams University

Faculty of Medicine
Ain Shams University
2006

ACKNOWLEDGMENT

*First of all. I wish to express my sincere thanks to **GOD**.*

*I would like to express my deepest gratitude and profound appreciation to **Professor Dr. Yehia El-Shazly**, Professor of internal medicine, Ain Shams University for his great support, continuous advice and encouragement. His experience certainly made this work not only possible but also enjoyable. I owe him much I can express.*

*I would like to express my deepest gratitude and profound appreciation to **Dr. Khaled El-Karmoty**, Assistant Professor of internal medicine, Ain Shams University for his kind support, continuous advice and encouragement.*

*I would express my deepest gratitude to **Dr. Ahmed Ali Monis**,*

*Lecturer of internal medicine, Ain
Shams University for his comprehensive
help through the work.*

AIM OF THE WORK

1. Determine the incidence of occult HBV DNA with absent HBsAg among chronic HCV patients receiving combination therapy.
2. Relation to response to treatment will be studied.

Contents

Title	Page
▪ List of abbreviations	I
▪ List of tables	II
▪ List of figures and graphs	III
▪ Introduction	1
▪ Aim of the work	3
▪ Review of Literature	4
Chapter I - Therapy of chronic hepatitis C	4
I - Interferons	6
A) Types of human interferons	7
B) Mechanism of action of interferon	9
C) Interferon production in acute and chronic hepatitis	10
D) Availability of interferons	10
E) Administration of interferons	11
F) Contraindications to interferon therapy	11
G) Side effects to interferon therapy	12
H) Usefulness of alpha interferon for treatment of hepatitis C	17
I) Pegylated Interferons	21
J) Pegylated interferon alpha plus ribavirin as the first line of treatment in naïve patient with chronic hepatitis Cc	23
K) Definitions of interferon response	24
L) Predictors of interferon efficacy	25
II- Ribavirin and its role as adjuvant agent with interferon in therapy of chronic hepatitis C	30
Chapter II – Occult hepatitis B	33
Section I- Hepatitis B Virus	33
A) Virology	33
B) Epidemiology	35
C) Risk factors of HBV transmission	37
D) Pathogenesis of HBV infection	38

E) Clinical Picture of HBV infection	39
F) Diagnosis of HBV infection	40
G) Prevention of HBV infection	44
Section II- Occult Hepatitis B	45
A) Introduction	45
B) HBsAg and DNA testing	46
C) Clinical Scenarios associated with occult HBV infection	48
D) Mechanism of occult HBV infection	50
E) Prevalence of occult HBV infection	53
F) Occult HBV infection and transmission of HBV infection	54
G) Occult HBV infection and related chronic liver disease	56
H) Occult HBV infection and HCC	60
Section III- Occult HBV infection and chronic HCV infection	62
▪ Patients and Methods	68
▪ Results	72
▪ Discussion	86
▪ Summary and Conclusion	96
▪ References	100
▪ Arabic Summary	132

List of Abbreviations

α -INF	Alpha interferon
μ g	Microgram
μ mol/L	Micro mill mol
AA	Amino acids
AASLD	American Association for Study of Liver Diseases
ALP	Alkaline phosphates
ALT	Alanine aminotransferase
Anti-HBc	Hepatitis B core antibody
Anti-HBe	Hepatitis B e antibody
Anti-HBs	Hepatitis B surface antibody
Anti-HCV	Antibodies against hepatitis C virus
AST	Aspartate aminotransferase
BMI	Body mass index
cccDNA	Covalently closed circular DNA
CTLs	Cytotoxic T lymphocytes
DNA	Deoxyribonucleic acid
ELISA	Enzyme linked immunosorbant assay
EVR	Early virological response
g/dl	Gram per deciliter
HBcAg	Hepatitis B core antigen
HBeAg	Hepatitis e antigen
HBIG	Hepatitis B Immune Globulin
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HDV	Hepatitis Delta virus
HLA	Human leukocyte antigen
HS	Highly significant
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IU/ml	International unit per milliliter

Kd	Kilo Dalton
Kg	Kilogram
LCF	Liver cell failure
mg/dL	Milligram per deciliter
MIU	Million international unit
ml	Milliliter
ng	Nanogram
NK	Natural killer
NS	Non significant
OAS	oligo-adenylate synthetase
PBMCs	periphral blood mononuclear cells
PC	Prothrombin concentration
PCR	Polymerase chain reaction
PEG	Polyethylene glycol
Pg	Pico gram
QN	Quantitative
RNA	Ribonucleic acid
S	Significant
SC	Subcutaneous
SD	Standard deviation
STD	Sexually transmitted diseases
SVR	Sustained virological response
T3	triiodothyronine
T4	thyroxine
TP	Total proteins
TSH	Thyroid stimulating hormone
WHO	World Health Organization
β	Beta

List of tables

Table	Title	Page
Table (1)	Possible factors predicting a favorable response to antiviral therapy in chronic HCV infection	7
Table (2)	Potential contraindications to pegylated interferon and ribavirin	13
Table (3)	Possible adverse effects of pegylated interferon and ribavirin therapy	19
Table (4)	Typical serological profile in patient with HBV infection	42
Table (5)	Clinical groups at risk of occult HBV infection	54
Table (6)	Clinical outcomes associated with occult hepatitis B in patients with chronic hepatitis C coinfection	65
Table (7)	Descriptive statistics	76
Table (8)	Showing comparison between responders and non-responders as regards age	77
Table (9)	Descriptive statistics showing the frequency of sex distribution	77
Table(10)	Showing comparison between responders and non-responders as regards sex distribution	78
Table (11)	Showing comparison between	79

	responders and non-responders as regards weight distribution	
Table (12)	Descriptive statistics showing the frequency of significant diseases	80
Table (13)	Showing comparison between responders and non-responders as regards presence of significant diseases	80
Table (14)	Descriptive statistics showing the frequency of serum ALT folds	81
Table (15)	Showing comparison between responders and non-responders as regards serum ALT folds	81
Table (16)	Showing comparison between responders and non-responders as regards serum ALT level	82
Table (17)	Descriptive statistics showing the frequency of early response at 12 weeks	82
Table (18)	Showing comparison between responders and non-responders as regards response at 12 weeks	83
Table (19)	Descriptive statistics showing the frequency of response at 48 weeks	84
Table (20)	Showing a comparison between responders and non responders as	84

	regards response at 48 week	
Table (21)	Descriptive statistics showing the frequency of HBV DNA at 48 weeks	85
Table (22)	Showing comparison between responders and non-responders as regards presence of HBV DNA	85

List of figures and graphs

Figure	Title	Page
Figure (1)	Genome of hepatitis B virus	34
Figure (2)	Mechanism of Hepatitis B virus replication and the site of action of different treatment methods	35
Figure (3)	Geographic distribution of chronic hepatitis B infection, shown as HBsAg prevalence	36
Figure (4)	A model of occult hepatitis B highlighting the potential role of the immune system	48
Graph (1)		
Graph (2)		
Graph (3)		
Graph (4)		
Graph (5)		
Graph (6)		
Graph (7)		

INTRODUCTION

Hepatitis B & C are the most common causes of chronic liver disease world wide. Acute infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) may result in chronic infection. Co-infection of both viruses can occur because of shared routes of infection e.g. blood Transfusion, hemodialysis or organ Transplant (**Crockett and Keefe, 2005**).

Hepatitis B virus infections in patients who lack detectable hepatitis B surface Ag (HBsAg) with or without serologic markers of previous infection (HBsAb or hepatitis B core Ab) are called occult infection. Lack of circulating HBsAg in such patients are unknown but recent observation have suggested that the lack of HBsAg may be due to rearrangement of HBV genome that interfere with gene expression or lead to production of an antigenically modified S protein. Occult HBV infection has been frequently identified in patients with HCV related chronic hepatitis; considerable data suggests that this occult infection may contribute to chronic liver damage, development of hepatocellular carcinoma and diminished response to interferon. (**Cacciola et al., 1999**).

Detection of occult HBV infection is done by detection of HBV DNA through PCR in serum or liver biopsy, since viral DNA levels in occult HBV are very low, the identification of occult HBV is strongly dependant on specificity and sensitivity of the assay (**Torbenson and Thomas, 2002**).

In patients chronically infected with HCV, combination therapy with ribavirin plus alpha 2 interferon has greatly

improved the rate of sustained biochemical and virological response compared to those achieve with interferon monotherapy (*Larrat et al., 2003*).

The clinical significance of occult hepatitis B alone or in combination with HCV infection remains unsettled, previous epidemiologic and molecular studies have indicated that persistence of HBV infection may be associated with the development of HCC in HBsAg negative patients (*Kao et al., 2002*).

CHAPTER I

THERAPY OF CHRONIC HEPATITIS C

Introduction

Hepatitis due to hepatitis C virus (HCV) infection is an important public health problem worldwide (**Andreone et al., 1999**). HCV causes hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), and globally reported anti-HCV prevalence ranges between 1% and 3% (**Leung, 2002**). Its prevalence varies from 0.01% in United Kingdom to 17%-20% in Egypt (**Abdel-Wahab et al., 1994**).

Despite the introduction of laboratory tests to screen national blood supplies, HCV remains the most common cause of post-transfusion hepatitis worldwide because unscreened blood and blood products are still used in many developing countries or economies in transition (**Kim, 2002**).

The WHO has estimated that 170 million people worldwide are infected with hepatitis C virus (HCV). Reports indicate that the prevalence rates for anti-HCV ranges from 0.5–1% in low prevalence areas such as North America to >20% in high prevalence areas such as Egypt (**World Health Organization, 1999**). Acute infection with HCV is followed by chronic infection in 80% of cases with increased risk for liver cirrhosis and hepatocellular carcinoma (**Liang et al., 2000**).

HCV genotype differences are of considerable clinical significance because they affect responses to antiviral therapy. Genotype 4 predominates throughout the Middle East and parts of Africa (**Abdel-Aziz et al., 2000**), often in association with high population prevalence as in Egypt (**Habib et al., 2001**),